MoonLake Immunotherapeuti...

39.54
-0.46 (-1.15%)
At close: Apr 22, 2025, 3:59 PM
39.45
-0.23%
After-hours: Apr 22, 2025, 04:05 PM EDT

Company Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.

It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation.

The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.

MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics
MoonLake Immunotherapeutics logo
Country CH
IPO Date Oct 20, 2020
Industry Biotechnology
Sector Healthcare
Employees 100
CEO Dr. Jorge Santos da Silva Ph.D.

Contact Details

Address:
Dorfstrasse 29
Zug,
CH
Website https://www.moonlaketx.com

Stock Details

Ticker Symbol MLTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001821586
CUSIP Number 61559X104
ISIN Number KY61559X1045
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Jorge Santos da Silva Ph.D. Co-Founder, Chief Executive Officer & Director
Matthias Bodenstedt Chief Financial Officer
Carla Bretes Director of Investor Relations & External Communications
Dr. Kristian Reich M.D., Ph.D. Co-Founder & Chief Scientific Officer
Joana Cortez Senior Director Legal & Compliance
Luciana Marques Director of HR, People & Culture
Nicolas Mosimann Ph.D. General Counsel
Nuala Brennan Chief Clinical Development Officer
Oliver Daltrop Ph.D. Chief Operations Officer
Tino Anthamatten Vice President of Marketing, Market Access & Pricing

Latest SEC Filings

Date Type Title
Apr 03, 2025 8-K Current Report
Mar 03, 2025 4 Filing
Mar 03, 2025 4 Filing
Mar 03, 2025 4 Filing
Feb 26, 2025 10-K Annual Report
Feb 26, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 12, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 22, 2025 4 Filing
Dec 18, 2024 8-K Current Report